Equities
Health CarePharmaceuticals and Biotechnology
  • Price (MXN)2,260.00
  • Today's Change10.00 / 0.44%
  • Shares traded827.00
  • 1 Year change+22.58%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 19:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7,09313,1928,096
Total Receivables, Net11,07210,1109,230
Total Inventory6,3585,9115,953
Prepaid expenses------
Other current assets, total7,6456,5096,987
Total current assets32,16835,72230,266
Property, plant & equipment, net24,48822,76819,279
Goodwill, net21,19721,20421,264
Intangibles, net18,01120,26922,933
Long term investments1,5012,445966
Note receivable - long term------
Other long term assets9,3106,75210,986
Total assets106,675109,160105,694
LIABILITIES
Accounts payable3,9224,2644,609
Accrued expenses15,19213,60813,859
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,3721,9462,412
Other current liabilities, total5,2084,4212,992
Total current liabilities25,69424,23923,872
Total long term debt33,68328,74530,690
Total debt35,05530,69133,102
Deferred income tax8711,7953,441
Minority interest546773
Other liabilities, total8,7928,3239,434
Total liabilities69,09463,16967,510
SHAREHOLDERS EQUITY
Common stock1,7881,7881,788
Additional paid-in capital44,50944,37944,238
Retained earnings (accumulated deficit)53,89561,08153,696
Treasury stock - common(57450)(56489)(57109)
Unrealized gain (loss)--00
Other equity, total(5161)(4768)(4429)
Total equity37,58145,99138,184
Total liabilities & shareholders' equity106,675109,160105,694
Total common shares outstanding2,5322,5382,528
Treasury shares - common primary issue1,0451,0391,049
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.